CeNeRx raises $4.85M for TriRima trial, CNS agents

12/15/2011 | Pharmaceutical Business Review Online

CeNeRx BioPharma has secured $4.85 million in funding from investors including L Capital Partners and Omega Funds. The company will use the money to finish its second-phase trial of TriRima, its new antidepressant formulation, and to advance agents for disorders of the central nervous system.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR CLINICAL RESEARCH - 14000003MB
Abbott
Santa Clara, CA
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA